Analysts Set Nkarta, Inc. (NASDAQ:NKTX) PT at $15.00

Nkarta, Inc. (NASDAQ:NKTX) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $15.00.

A number of equities analysts recently weighed in on NKTX shares. RODMAN&RENSHAW upgraded shares of Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Needham & Company LLC decreased their price target on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Rodman & Renshaw assumed coverage on Nkarta in a research report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price objective for the company. HC Wainwright decreased their target price on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Finally, Mizuho cut their price target on Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a report on Thursday, November 21st.

Institutional Investors Weigh In On Nkarta

Several institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in shares of Nkarta by 252.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,063,362 shares of the company’s stock valued at $4,806,000 after purchasing an additional 761,349 shares during the last quarter. Franklin Resources Inc. purchased a new position in Nkarta during the third quarter worth $151,000. Barclays PLC increased its position in Nkarta by 161.4% during the third quarter. Barclays PLC now owns 232,566 shares of the company’s stock valued at $1,051,000 after acquiring an additional 143,608 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Nkarta by 3.0% in the third quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock valued at $5,294,000 after acquiring an additional 33,927 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Nkarta in the 3rd quarter worth about $223,000. 80.54% of the stock is owned by institutional investors.

Nkarta Price Performance

NKTX stock opened at $2.41 on Monday. Nkarta has a 1-year low of $2.08 and a 1-year high of $16.24. The business has a 50 day simple moving average of $2.84 and a two-hundred day simple moving average of $4.54. The company has a market capitalization of $170.07 million, a price-to-earnings ratio of -1.28 and a beta of 0.82.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.